Physician profile
Lee Brown Taylor
NPI 1750410700
$5,830.78
in general payments reported to CMS, 2019-2025
28 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $71.56 · 2021: $295 · 2022: $961 · 2023: $1,404 · 2024: $1,321 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,130.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $802.14 | 2021-2025 | Mitraclip, Cardiomems, Triclip |
| Novartis Pharmaceuticals Corporation | $731.08 | 2019-2025 | |
| Boston Scientific Corporation | $718.56 | 2019-2025 | Watchman Flx, Farapulse, Watchman |
| Amgen INC. | $664.02 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $545.12 | 2019-2025 | Lifevest |
| Philips North America LLC | $477.44 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck4) Mcot, (5091) Amb Mon & Diag Und |
| Heartflow, INC. | $234.98 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $219.47 | 2022-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $214.68 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $210.98 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.31 | 2020-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $119.04 | 2022-2024 | Onpattro |
| Pfizer INC. | $118.51 | 2019-2023 | |
| Abiomed | $107.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $51.66 | 2019-2024 | Farxiga |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $47.93 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $44.46 | 2024 | |
| Amarin Pharma, INC. | $42.24 | 2019-2021 | |
| Terumo Medical Corporation | $39.19 | 2019-2025 | Tr Band |
| Daiichi Sankyo INC. | $37.74 | 2019-2022 | |
| Atricure, INC. | $35.29 | 2024 | |
| Esperion Therapeutics, INC. | $35.22 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $34.56 | 2021-2025 | |
| Novo Nordisk INC | $34.51 | 2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $24.85 | 2024 | Optimizer |
| Sumitomo Pharma America, INC. | $19.31 | 2024 | Gemtesa |
| Kestra Medical Technology Services, INC. | $16.34 | 2025 | Assure Wcd |
| Cardiovascular Systems INC. | $10.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.